Arch Cancer Therapeutics Ltd

Arch Biopartners Inc., based in Toronto, is a late-stage clinical company focused on developing innovative treatments for acute kidney injury (AKI). With its lead drug candidates, LSALT peptide and Cilastatin, the company aims to significantly improve outcomes for patients at risk of this debilitating condition, which affects millions annually in the US and Europe. Dedicated to addressing organ inflammation, Arch Biopartners is advancing a therapeutic platform that targets key pathways involved in inflammation, including the DPEP1 enzyme. The company collaborates closely with the scientific community and research institutions to enhance the value of its therapeutic innovations and intellectual property for its investors. Generated from the website

SusGlobal Energy Corp, based in Toronto, Canada, is an industrial environmental and agricultural biotechnology company specializing in the development and commercialization of innovative waste to energy and regenerative product technologies globally. Their flagship product, SusGro, is an award-winning pathogen-free organic liquid fertilizer that aims to promote healthy growth through sustainable practices. With a focus on the circular economy, SusGlobal Energy Corp is committed to providing cutting-edge solutions for handling organic waste and maximizing the use of non-fossil carbon energy. Through strategic partnerships and a dedication to innovation, the company strives to establish itself as a trusted brand in the fertilizer, soil, and aquaculture markets, driving towards a more sustainable and environmentally conscious future. Generated from their website